Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | YAP1 | P46937 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PRMT5 | O14744 | 4/20 | 0.39 |
| ▸ | GUSB | P08236 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 2/20 | 0.38 |
| ▸ | GHSR | Q92847 | 2/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1104530 | 0.92 | YAP1 (0.44) | YAP1ALDH1A1PRMT5ADAM17GHSR | |
| SCHEMBL1104560 | 0.92 | YAP1 (0.44) | YAP1ALDH1A1PRMT5ADAM17GHSR | |
| SCHEMBL10167532 | 0.89 | YAP1 (0.44) | YAP1PRMT5ADAM17GHSRTP53 | |
| SCHEMBL10167537 | 0.87 | YAP1 (0.46) | YAP1PRMT5ADAM17GHSRTP53 | |
| SCHEMBL13172547 | 0.87 | YAP1 (0.44) | YAP1PRMT5ADAM17GHSRTP53 | |
| SCHEMBL14019388 | 0.87 | YAP1 (0.44) | YAP1PRMT5ADAM17GHSRTP53 | |
| SCHEMBL1104528 | 0.83 | YAP1 (0.48) | YAP1PRMT5ADAM17GHSRTP53 | |
| SCHEMBL1104540 | 0.83 | YAP1 (0.41) | YAP1ALDH1A1GUSBADAM17GHSR | |
| SCHEMBL483258 | 0.82 | PRMT5 (0.45) | YAP1PRMT5GHSRTP53 | |
| SCHEMBL4770854 | 0.82 | PRMT5 (0.45) | YAP1PRMT5GHSRTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153623-B2 | Compounds | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-8153623-B2 | Compounds | Convergence Pharmaceuticals Limited (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-20100324022-A1 | NOVEL COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-12-23 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-7803833-B2 | Compounds | GLAXO GROUP LIMITED (GB) | 2010-09-28 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
| US-20080293753-A1 | Novel Compounds | Convergence Pharmaceuticals Limited (GB) | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100324022-A1 | NOVEL COMPOUNDS | CYP46A1, NPC1, CYP11B1 | YAP1 1640/4885ALDH1A1 895/4885PRMT5 3104/4885 |
| US-20080293753-A1 | Novel Compounds | CACNA1E, CACNA1A, SCN1B | YAP1 3425/4885ALDH1A1 1652/4885PRMT5 319/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.